{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:04:18Z","timestamp":1792793058028,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000855","name":"University of Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Radioactive iodine (RAI) therapy is a critical component in the post-surgical management of thyroid cancer patients, as well as being a central therapeutic option in the treatment of hyperthyroidism. Previous work suggests that antithyroid drugs hinder the efficacy of RAI therapy in patients. However, the effects of other background medications on RAI treatment efficacy have not been evaluated. Therefore, we performed a systematic review and meta-analysis investigating the potential off-target effects of medication on RAI therapy in patients with thyroid cancer and hyperthyroidism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Systematic review and meta-analysis according to the 2020 PRISMA guidelines. Databases searched: MEDLINE, EMBASE and Cochrane Library for studies published between 2001 and 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-nine unique studies were identified. After screening, 17 studies with 3313 participants were included. One study investigated thyroid cancer, with the rest targeted to hyperthyroidism. The majority of studies evaluated the effects of antithyroid drugs; the other drugs studied included lithium, prednisone and glycididazole sodium. Antithyroid drugs were associated with negative impacts on post-RAI outcomes (n = 5 studies, RR = 0.81, p = 0.02). However, meta-analysis found moderate heterogeneity between studies (I2 = 51%, \u03c42 = 0.0199, p = 0.08). Interestingly, lithium (n = 3 studies), prednisone (n = 1 study) and glycididazole (n = 1 study) appeared to have positive impacts on post-RAI outcomes upon qualitative analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our systematic review strengthens previous work on antithyroid medication effects on RAI, and highlights that this field remains under researched especially for background medications unrelated to thyroid disease, with very few papers on non-thyroid medications published.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php<\/jats:uri>, identifier CRD42021274026.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1061555","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:36:26Z","timestamp":1672839386000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The potential interaction between medical treatment and radioiodine treatment success: A systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Riazul","family":"Zannat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Muzaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin L.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Brookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristien","family":"Boelaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah R.","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","unstructured":"Overactive thyroid (hyperthyroidism)- treatment- NHS2019"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/379458a0","article-title":"Cloning and characterization of the thyroid iodide transporter","volume":"379","author":"Dai","year":"1996","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1471-2407-7-137","article-title":"PI3K activation is associated with intracellular sodium\/iodide symporter protein expression in breast cancer","volume":"7","author":"Knostman","year":"2007","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism","volume":"92","author":"Durante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1371","article-title":"Excess iodide induces an acute inhibition of the Sodium\/Iodide symporter in thyroid Male rat cells by increasing reactive oxygen species","volume":"156","author":"Arriagada","year":"2015","journal-title":"Endocrinology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0360","article-title":"Cyclic AMP\u2013response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells","volume":"22","author":"Passon","year":"2012","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-022516-034125","article-title":"The Sodium\/Iodide symporter (NIS): Molecular physiology and preclinical and clinical applications","volume":"79","author":"Ravera","year":"2017","journal-title":"Annu Rev Physiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0399","article-title":"Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer","volume":"21","author":"Zhang","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3547","article-title":"The miR-146b-3p\/PAX8\/NIS regulatory circuit modulates the differentiation phenotype and function of thyroid cells during carcinogenesis","volume":"75","author":"Riesco-Eizaguirre","year":"2015","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in BRAF -mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: Results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4103\/wjnm.WJNM_104_20","article-title":"Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience","volume":"20","author":"Lubin","year":"2021","journal-title":"World J Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/bmj.39114.670150.BE","article-title":"Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials","volume":"334","author":"Walter","year":"2007","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"105509","DOI":"10.1016\/j.envint.2020.105509","article-title":"Associations between urine phthalate metabolites and thyroid function in pregnant women and the influence of iodine status","volume":"137","author":"Villanger","year":"2020","journal-title":"Environ Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.02110927","article-title":"Health effects assessment for environmental perchlorate contamination: the dose response for inhibition of thyroidal radioiodine uptake in humans","volume":"110","author":"Greer","year":"2002","journal-title":"Environ Health Perspect"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2007.0105","article-title":"Clinical studies of exposure to perchlorate in the united states","volume":"17","author":"Braverman","year":"2007","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2021.07.016","article-title":"Targeting non-canonical pathways as a strategy to modulate the sodium iodide symporter","volume":"29","author":"Read","year":"2022","journal-title":"Cell Chem Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B23","article-title":"United Kingdom. CASP Cohort Study Checklist","year":"2022"},{"key":"B24","article-title":"United Kingdom. CASP Case Control Study Checklist","year":"2022"},{"key":"B25","article-title":"Glycididazole sodium combined with radioiodine therapy for patients with differentiated thyroid carcinoma (DTC)","volume":"8","author":"Wen","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7707","article-title":"The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in graves\u2019 hyperthyroidism: One-year follow-up of a prospective, randomized study","volume":"86","author":"Andrade","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0226","article-title":"Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: An evaluation by a randomized trial","volume":"91","author":"Bonnema","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2362.2010.02452.x","article-title":"A randomized trial evaluating a block-replacement regimen during radioiodine therapy: BLOCK-REPLACEMENT REGIMEN DURING RADIOIODINE THERAPY","volume":"41","author":"Bonnema","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/105072502753522365","article-title":"The effect of methimazole on cure rates after radioiodine treatment for graves\u2019 hyperthyroidism: A randomized clinical trial","volume":"12","author":"Braga","year":"2002","journal-title":"Thyroid"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-924238","article-title":"Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of graves\u2019 disease: Results of a prospective study","volume":"114","author":"Eschmann","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100565","article-title":"Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in graves\u2019 disease and toxic nodular goitre","volume":"28","author":"K\u00f6rber","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1089\/1050725041517093","article-title":"Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with graves\u2019 disease","volume":"14","author":"Santos","year":"2004","journal-title":"Thyroid"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnm.0000183795.59097.42","article-title":"High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in graves\u2019 disease","volume":"26","author":"Zantut-Wittmann","year":"2005","journal-title":"Nucl Med Commun"},{"key":"B34","article-title":"The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment (131I) in hyperthyroid patients","volume":"61","author":"Oszukowska","year":"2010","journal-title":"Endokrynol Pol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/2230-8210.139234","article-title":"Radioiodine therapy in patients with graves\u2019 disease and the effects of prior carbimazole therapy","volume":"18","author":"Karyampudi","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0092-8","article-title":"Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison","volume":"33","author":"Walter","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2008.02061.x","article-title":"Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models","volume":"39","author":"Walter","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/105072502760043486","article-title":"A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism","volume":"12","author":"Bal","year":"2002","journal-title":"Thyroid"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020580","article-title":"Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with graves\u2019 disease","volume":"87","author":"Bogazzi","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1655","article-title":"Impact of lithium on efficacy of radioactive iodine therapy for graves\u2019 disease: A cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal","volume":"95","author":"Bogazzi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5603\/NMR.2011.0002","article-title":"Lithium carbonate pre-treatment in 131-I therapy of hyperthyroidism","volume":"14","author":"P\u0142azi\u0144ska","year":"2011","journal-title":"Nucl Med Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1061555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:36:31Z","timestamp":1672839391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1061555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":42,"alternative-id":["10.3389\/fendo.2022.1061555"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1061555","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"1061555"}}